KD Logo

Chief Executive Officer Zanganeh Mahkam acquired 54,321 shares of Summit Therapeutics Inc [SMMT]

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Summit Therapeutics Inc shares valued at $201,874 were purchased by Zanganeh Mahkam on Mar 27 ’24. At $3.72 per share, Zanganeh Mahkam acquired 54,321 shares. The insider’s holdings grew to 24,923,800 shares worth approximately $173.22 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Also, Zanganeh Mahkam purchased 26,000 shares, netting a total of over 96,720 in proceeds. Following the buying of shares at $3.72 each, the insider now holds 520,814 shares.

Before that, Dhingra Ankur had added 100,000 shares to its account. In a trade valued at $375,000, the Chief Financial Officer bought Summit Therapeutics Inc shares for $3.75 each. Upon closing the transaction, the insider’s holdings increased to 100,000 shares, worth approximately $2.47 million.

As published in their initiating research note from Citigroup on May 07, 2024, Summit Therapeutics Inc [SMMT] has been a Buy and the price target has been revised to $7. Analysts at Stifel started covering the stock with ‘”a Buy”‘ outlook in a report released in late March. As of June 28, 2018, Janney has decreased its “Buy” rating to a “Neutral” for SMMT. Earlier on May 02, 2018, Janney initiated its rating. Their recommendation was “a Buy” for SMMT stock.

Analyzing SMMT Stock Performance

During the last five days, there has been a drop of approximately -10.55%. Over the course of the year, Summit Therapeutics Inc shares have jumped approximately 166.28%. Shares of the company reached a 52-week high of $11.25 on 05/30/24 and a 52-week low of $2.10 on 05/28/24. A 50-day SMA is recorded $6.05, while a 200-day SMA reached $3.77. Nevertheless, trading volume fell to 2.15 million shares from 2.67 million shares the previous day.

Support And Resistance Levels for Summit Therapeutics Inc (SMMT)

According to the 24-hour chart, there is a support level at 6.53, which, if violated, would cause prices to drop to 6.18. In the upper region, resistance lies at 7.49. The next price resistance is at 8.10. RSI (Relative Strength Index) is 47.39 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.34, which suggests the price will decrease in the coming days. Percent R is at 94.47%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Most Popular